Standard aplastic anemia therapy improves patient outcomes better than newer version
A comparison clinical study of two aplastic anemia treatments found that ATGAM, currently the only licensed aplastic anemia drug in the United States, improved blood cell counts and survival significantly more than Thymoglobulin, a similar but reportedly more potent treatment. The research was carried out by the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health.
This page was last updated on Friday, January 21, 2022